These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29239896)

  • 1. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
    Neogi U; Singh K; Aralaguppe SG; Rogers LC; Njenda DT; Sarafianos SG; Hejdeman B; Sönnerborg A
    AIDS; 2018 Feb; 32(4):469-476. PubMed ID: 29239896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
    Smith SJ; Zhao XZ; Burke TR; Hughes SH
    Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable
    Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
    You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
    PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
    Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.
    Zhang WW; Cheung PK; Oliveira N; Robbins MA; Harrigan PR; Shahid A
    J Infect Dis; 2018 Oct; 218(11):1773-1776. PubMed ID: 30010985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
    Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
    Yang LL; Li Q; Zhou LB; Chen SQ
    Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV drug resistance against strand transfer integrase inhibitors.
    Anstett K; Brenner B; Mesplede T; Wainberg MA
    Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Mbhele N; Chimukangara B; Gordon M
    Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
    Le Hingrat Q; Collin G; Lê M; Peytavin G; Visseaux B; Bertine M; Tubiana R; Karmochkine M; Valin N; Collin F; Lemaignen A; Bernard L; Damond F; Matheron S; Descamps D; Charpentier C;
    Clin Infect Dis; 2019 Aug; 69(4):657-667. PubMed ID: 30383215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review.
    Blanco-Arévalo JL; García-Deltoro M; Torralba M; Vélez-Díaz-Pallarés M; Castro A; Rubio-Rodríguez D; Rubio-Terrés C
    AIDS Rev; 2024; 26(2):67-79. PubMed ID: 39134019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.